Targeting the Oral Mucosa: Emerging Drug Delivery Platforms and the Therapeutic Potential of Glycosaminoglycans
Pharmaceutics · 17.09.2025 · 17 (9) · 1212
DOI: 10.3390/pharmaceutics17091212 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 17.09.2025. Verfasst von Bruno Špiljak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Medicine, University of Zagreb School of Dental Medicine, 10000 Zagreb, Croatia. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 295 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Research into oral mucosa-targeted drug delivery systems (DDS) is rapidly evolving, with growing emphasis on enhancing bioavailability and precision targeting while overcoming the unique anatomical and physiological barriers of the oral environment. Despite considerable progress, challenges such as enzymatic degradation, limited mucosal penetration, and solubility issues continue to hinder therapeutic success. Recent advancements have focused on innovative formulation strategies—including nanoparticulate and biomimetic systems—to improve delivery efficiency and systemic absorption. Simultaneously, smart and stimuli-responsive materials are emerging, offering dynamic, environment-sensitive drug release profiles. One particularly promising area involves the application of glycosaminoglycans, a class of naturally derived polysaccharides with excellent biocompatibility, mucoadhesive properties, and hydrogel-forming capacity. These materials not only enhance drug residence time at the mucosal site but also enable controlled release kinetics, thereby improving therapeutic outcomes. However, critical research gaps remain: standardized, clinically meaningful mucoadhesion/permeation assays and robust in vitro–in vivo correlations are still lacking; long-term stability, batch consistency of GAGs, and clear regulatory classification (drug, device, or combination) continue to impede scale-up and translation. Patient-centric performance—palatability, mouthfeel, discreet wearability—and head-to-head trials versus standard care also require systematic evaluation to guide adoption. Overall, converging advances in GAG-based films, hydrogels, and nanoengineered carriers position oral mucosal delivery as a realistic near-term option for precision local and selected systemic therapies—provided the field resolves standardization, stability, regulatory, and usability hurdles.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oral Medicine, University of Zagreb School of Dental Medicine, 10000 Zagreb, Croatia.
- Faculty of Textile Technology, University of Zagreb, 10000 Zagreb, Croatia.
- Department of Pharmacology, University of Zagreb School of Dental Medicine, 10000 Zagreb, Croatia.
- Dental Polyclinic Zagreb, 10000 Zagreb, Croatia.
- University of Zagreb School of Dental Medicine, 10000 Zagreb, Croatia.
ORCID-Profile: Bruno Špiljak, Maja Somogyi Škoc, Iva Rezić Meštrović, Krešimir Bašić, Ivana Šutej
Zitieren
APA
Špiljak, B., Somogyi Škoc, M., Rezić Meštrović, I., Bašić, K., Bando, I., & Šutej, I. (2025). Targeting the Oral Mucosa: Emerging Drug Delivery Platforms and the Therapeutic Potential of Glycosaminoglycans. Pharmaceutics, 17(9), 1212. https://doi.org/10.3390/pharmaceutics17091212
Vancouver
Špiljak B, Somogyi Škoc M, Rezić Meštrović I, Bašić K, Bando I, Šutej I. Targeting the Oral Mucosa: Emerging Drug Delivery Platforms and the Therapeutic Potential of Glycosaminoglycans. Pharmaceutics. 2025;17(9):1212. doi:10.3390/pharmaceutics17091212
BibTeX
@article{piljak2025,
author = {Špiljak, Bruno and Somogyi Škoc, Maja and Rezić Meštrović, Iva and Bašić, Krešimir and Bando, Iva and Šutej, Ivana},
title = {Targeting the Oral Mucosa: Emerging Drug Delivery Platforms and the Therapeutic Potential of Glycosaminoglycans},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {9},
pages = {1212},
doi = {10.3390/pharmaceutics17091212}
}
EUVIMED